Compass Therapeutics

Compass Therapeutics

CMPX· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock +270.3% in FY2025

Thomas J. Schuetz, M.D., Ph.D. is the CEO of Compass Therapeutics and was paid $5.1M in FY2025 (Dec), up 65%.

Pay$100 in the stock at the end of FY21 → $546
CEO pay is from each Compass Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives3

See all
  1. 1Thomas J. Schuetz, M.D., Ph.D.FY2025
  2. 2Barry ShinFY2025
  3. 3Jonathan AndermanFY2024

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Compass Therapeutics paid its 2 named executives $6.5M in total in FY2025 (Dec). CEO Thomas J. Schuetz, M.D., Ph.D. was paid $5.1M of that.

Name
Thomas J. Schuetz, M.D., Ph.D.Chief Executive OfficerNot disclosed
Barry ShinChief Financial OfficerNot disclosed
Jonathan AndermanGeneral Counsel and Corporate SecretaryNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers

No disclosed peer group

No proxy on file names a pay peer group for Compass Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.

Board1

See all
  • Thomas J. Schuetz, M.D., Ph.D.Director · 9 yr on the boardNot independent—Paid as an executive

The board of the latest proxy (FY2023).

Activity

Filings6

See all
Proxy statementDEF 14AApr 29, 2026FY2025
Annual report10-KMar 5, 2026FY2025
Proxy statementDEF 14AApr 29, 2025FY2024
Annual report10-KFeb 27, 2025FY2024
Proxy statementDEF 14AApr 29, 2024FY2023
Annual report10-KMar 21, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data